Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells.
Rotolo R, Leuci V, Donini C, Galvagno F, Massa A, De Santis MC, Peirone S, Medico G, Sanlorenzo M, Vujic I, Gammaitoni L, Basiricò M, Righi L, Riganti C, Salaroglio IC, Napoli F, Tabbò F, Mariniello A, Vigna E, Modica C, D'Ambrosio L, Grignani G, Taulli R, Hirsch E, Cereda M, Aglietta M, Scagliotti GV, Novello S, Bironzo P, Sangiolo D. Rotolo R, et al. Among authors: riganti c. Clin Cancer Res. 2023 Feb 1;29(3):621-634. doi: 10.1158/1078-0432.CCR-22-0761. Clin Cancer Res. 2023. PMID: 36165915 Free PMC article.
Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment.
Battaglia L, Muntoni E, Chirio D, Peira E, Annovazzi L, Schiffer D, Mellai M, Riganti C, Salaroglio IC, Lanotte M, Panciani P, Capucchio MT, Valazza A, Biasibetti E, Gallarate M. Battaglia L, et al. Among authors: riganti c. Nanomedicine (Lond). 2017 Mar;12(6):639-656. doi: 10.2217/nnm-2016-0380. Epub 2017 Feb 10. Nanomedicine (Lond). 2017. PMID: 28186465
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.
Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F, Taulli R. Riganti C, et al. Oncoimmunology. 2017 Nov 27;7(3):e1398874. doi: 10.1080/2162402X.2017.1398874. eCollection 2018. Oncoimmunology. 2017. PMID: 29399399 Free PMC article.
Metabolic Alterations in a Slow-Paced Model of Pancreatic Cancer-Induced Wasting.
Wyart E, Reano S, Hsu MY, Longo DL, Li M, Hirsch E, Filigheddu N, Ghigo A, Riganti C, Porporato PE. Wyart E, et al. Among authors: riganti c. Oxid Med Cell Longev. 2018 Feb 26;2018:6419805. doi: 10.1155/2018/6419805. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 29682162 Free PMC article.
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
Kopecka J, Salaroglio IC, Righi L, Libener R, Orecchia S, Grosso F, Milosevic V, Ananthanarayanan P, Ricci L, Capelletto E, Pradotto M, Napoli F, Di Maio M, Novello S, Rubinstein M, Scagliotti GV, Riganti C. Kopecka J, et al. Among authors: riganti c. Lung Cancer. 2018 Jun;120:34-45. doi: 10.1016/j.lungcan.2018.03.022. Epub 2018 Mar 26. Lung Cancer. 2018. PMID: 29748013 Free article.
297 results